In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
The Investment Company Institute this week made public a set of recommendations to reform and modernize the Investment Company Act of 1940, which has not been ...
Securities brokerage firms are a critical part of the financial landscape, as they provide a vast array of products and services to the financial services industry, ...
The percentage of female independent directors serving on mutual fund boards has increased impressively in recent years, jumping from about 20% 10 years ago to nearly 40% ...
As mutual fund boards prepare for their next quarterly meetings over the coming weeks, they likely are gathering talking points on several of President Trump's initiatives ...